Discovery of Potent and Selective 7‑Azaindole Isoindolinone-Based PI3Kγ Inhibitors
The successful application of immunotherapy in the treatment of cancer relies on effective engagement of immune cells in the tumor microenvironment. Phosphoinositide 3-kinase γ (PI3Kγ) is highly expressed in tumor-associated macrophages, and its expression levels are associated with tumor immunosupp...
Gespeichert in:
| Veröffentlicht in: | ACS medicinal chemistry letters 2020-11, Vol.11 (11), p.2244-2252 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2252 |
|---|---|
| container_issue | 11 |
| container_start_page | 2244 |
| container_title | ACS medicinal chemistry letters |
| container_volume | 11 |
| creator | Miles, Dillon H Yan, Xuelei Thomas-Tran, Rhiannon Fournier, Jeremy Sharif, Ehesan U Drew, Samuel L Mata, Guillaume Lawson, Kenneth V Ginn, Elaine Wong, Kent Soni, Divyank Dhanota, Puja Shaqfeh, Stefan G Meleza, Cesar Chen, Ada Pham, Amber T Park, Timothy Swinarski, Debbie Banuelos, Jesus Schindler, Ulrike Walters, Matthew J Walker, Nigel P Zhao, Xiaoning Young, Stephen W Chen, Jie Jin, Lixia Leleti, Manmohan Reddy Powers, Jay P Jeffrey, Jenna L |
| description | The successful application of immunotherapy in the treatment of cancer relies on effective engagement of immune cells in the tumor microenvironment. Phosphoinositide 3-kinase γ (PI3Kγ) is highly expressed in tumor-associated macrophages, and its expression levels are associated with tumor immunosuppression and growth. Selective inhibition of PI3Kγ offers a promising strategy in immuno-oncology, which has led to the development of numerous potent PI3Kγ inhibitors with variable selectivity profiles. To facilitate further investigation of the therapeutic potential of PI3Kγ inhibition, we required a potent and PI3Kγ-selective tool compound with sufficient metabolic stability for use in future in vivo studies. Herein, we describe some of our efforts to realize this goal through the systematic study of SARs within a series of 7-azaindole-based PI3Kγ inhibitors. The large volume of data generated from this study helped guide our subsequent lead optimization efforts and will inform further development of PI3Kγ-selective inhibitors for use in immunomodulation. |
| doi_str_mv | 10.1021/acsmedchemlett.0c00387 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7667872</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2463098856</sourcerecordid><originalsourceid>FETCH-LOGICAL-a434t-8def5a135aa89cf40ec0dd16aa02a979c57d20eb879966cdc7b27749cb78cf2b3</originalsourceid><addsrcrecordid>eNqFUUtKBDEUDKL4v4L00k1rOunOZyP4d1BwQGcd0slrJ9KTaNIzoCuv4Fm8h4fwJLbOILpy9QpeVb1HFUI7Bd4rMCn2tUkTsGYMkxa6bg8bjKngS2i9kKXIK8Gr5V94DW2kdI8xk5zjVbRGKSlKQdk6Gp24ZMIM4lMWmmwYOvBdpr3NbqAF07kZZPzj5fXwWTtvQwvZIIVv5HzwkB_pBDYbDujl-1s28GNXuy7EtIVWGt0m2F7MTTQ6O709vsivrs8Hx4dXuS5p2eXCQlPpglZaC2maEoPB1hZMa0y05NJU3BIMteBSMmas4TXhvJSm5sI0pKab6GDu-zCtv-Lon4-6VQ_RTXR8UkE79Xfj3VjdhZnijHHBSW-wuzCI4XEKqVOTPg9oW-0hTJMiJaNYClGxnsrmVBNDShGanzMFVl-dqL-dqEUnvZDMhf1e3Ydp9H0k_4k-AfXQl_k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2463098856</pqid></control><display><type>article</type><title>Discovery of Potent and Selective 7‑Azaindole Isoindolinone-Based PI3Kγ Inhibitors</title><source>ACS Publications</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Miles, Dillon H ; Yan, Xuelei ; Thomas-Tran, Rhiannon ; Fournier, Jeremy ; Sharif, Ehesan U ; Drew, Samuel L ; Mata, Guillaume ; Lawson, Kenneth V ; Ginn, Elaine ; Wong, Kent ; Soni, Divyank ; Dhanota, Puja ; Shaqfeh, Stefan G ; Meleza, Cesar ; Chen, Ada ; Pham, Amber T ; Park, Timothy ; Swinarski, Debbie ; Banuelos, Jesus ; Schindler, Ulrike ; Walters, Matthew J ; Walker, Nigel P ; Zhao, Xiaoning ; Young, Stephen W ; Chen, Jie ; Jin, Lixia ; Leleti, Manmohan Reddy ; Powers, Jay P ; Jeffrey, Jenna L</creator><creatorcontrib>Miles, Dillon H ; Yan, Xuelei ; Thomas-Tran, Rhiannon ; Fournier, Jeremy ; Sharif, Ehesan U ; Drew, Samuel L ; Mata, Guillaume ; Lawson, Kenneth V ; Ginn, Elaine ; Wong, Kent ; Soni, Divyank ; Dhanota, Puja ; Shaqfeh, Stefan G ; Meleza, Cesar ; Chen, Ada ; Pham, Amber T ; Park, Timothy ; Swinarski, Debbie ; Banuelos, Jesus ; Schindler, Ulrike ; Walters, Matthew J ; Walker, Nigel P ; Zhao, Xiaoning ; Young, Stephen W ; Chen, Jie ; Jin, Lixia ; Leleti, Manmohan Reddy ; Powers, Jay P ; Jeffrey, Jenna L</creatorcontrib><description>The successful application of immunotherapy in the treatment of cancer relies on effective engagement of immune cells in the tumor microenvironment. Phosphoinositide 3-kinase γ (PI3Kγ) is highly expressed in tumor-associated macrophages, and its expression levels are associated with tumor immunosuppression and growth. Selective inhibition of PI3Kγ offers a promising strategy in immuno-oncology, which has led to the development of numerous potent PI3Kγ inhibitors with variable selectivity profiles. To facilitate further investigation of the therapeutic potential of PI3Kγ inhibition, we required a potent and PI3Kγ-selective tool compound with sufficient metabolic stability for use in future in vivo studies. Herein, we describe some of our efforts to realize this goal through the systematic study of SARs within a series of 7-azaindole-based PI3Kγ inhibitors. The large volume of data generated from this study helped guide our subsequent lead optimization efforts and will inform further development of PI3Kγ-selective inhibitors for use in immunomodulation.</description><identifier>ISSN: 1948-5875</identifier><identifier>EISSN: 1948-5875</identifier><identifier>DOI: 10.1021/acsmedchemlett.0c00387</identifier><identifier>PMID: 33214836</identifier><language>eng</language><publisher>American Chemical Society</publisher><subject>Letter</subject><ispartof>ACS medicinal chemistry letters, 2020-11, Vol.11 (11), p.2244-2252</ispartof><rights>2020 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a434t-8def5a135aa89cf40ec0dd16aa02a979c57d20eb879966cdc7b27749cb78cf2b3</citedby><cites>FETCH-LOGICAL-a434t-8def5a135aa89cf40ec0dd16aa02a979c57d20eb879966cdc7b27749cb78cf2b3</cites><orcidid>0000-0002-3093-6665 ; 0000-0001-9249-5984 ; 0000-0002-2605-6745 ; 0000-0001-8064-8699 ; 0000-0001-5094-6337</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.0c00387$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00387$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,2766,27078,27926,27927,53793,53795,56740,56790</link.rule.ids></links><search><creatorcontrib>Miles, Dillon H</creatorcontrib><creatorcontrib>Yan, Xuelei</creatorcontrib><creatorcontrib>Thomas-Tran, Rhiannon</creatorcontrib><creatorcontrib>Fournier, Jeremy</creatorcontrib><creatorcontrib>Sharif, Ehesan U</creatorcontrib><creatorcontrib>Drew, Samuel L</creatorcontrib><creatorcontrib>Mata, Guillaume</creatorcontrib><creatorcontrib>Lawson, Kenneth V</creatorcontrib><creatorcontrib>Ginn, Elaine</creatorcontrib><creatorcontrib>Wong, Kent</creatorcontrib><creatorcontrib>Soni, Divyank</creatorcontrib><creatorcontrib>Dhanota, Puja</creatorcontrib><creatorcontrib>Shaqfeh, Stefan G</creatorcontrib><creatorcontrib>Meleza, Cesar</creatorcontrib><creatorcontrib>Chen, Ada</creatorcontrib><creatorcontrib>Pham, Amber T</creatorcontrib><creatorcontrib>Park, Timothy</creatorcontrib><creatorcontrib>Swinarski, Debbie</creatorcontrib><creatorcontrib>Banuelos, Jesus</creatorcontrib><creatorcontrib>Schindler, Ulrike</creatorcontrib><creatorcontrib>Walters, Matthew J</creatorcontrib><creatorcontrib>Walker, Nigel P</creatorcontrib><creatorcontrib>Zhao, Xiaoning</creatorcontrib><creatorcontrib>Young, Stephen W</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Jin, Lixia</creatorcontrib><creatorcontrib>Leleti, Manmohan Reddy</creatorcontrib><creatorcontrib>Powers, Jay P</creatorcontrib><creatorcontrib>Jeffrey, Jenna L</creatorcontrib><title>Discovery of Potent and Selective 7‑Azaindole Isoindolinone-Based PI3Kγ Inhibitors</title><title>ACS medicinal chemistry letters</title><addtitle>ACS Med. Chem. Lett</addtitle><description>The successful application of immunotherapy in the treatment of cancer relies on effective engagement of immune cells in the tumor microenvironment. Phosphoinositide 3-kinase γ (PI3Kγ) is highly expressed in tumor-associated macrophages, and its expression levels are associated with tumor immunosuppression and growth. Selective inhibition of PI3Kγ offers a promising strategy in immuno-oncology, which has led to the development of numerous potent PI3Kγ inhibitors with variable selectivity profiles. To facilitate further investigation of the therapeutic potential of PI3Kγ inhibition, we required a potent and PI3Kγ-selective tool compound with sufficient metabolic stability for use in future in vivo studies. Herein, we describe some of our efforts to realize this goal through the systematic study of SARs within a series of 7-azaindole-based PI3Kγ inhibitors. The large volume of data generated from this study helped guide our subsequent lead optimization efforts and will inform further development of PI3Kγ-selective inhibitors for use in immunomodulation.</description><subject>Letter</subject><issn>1948-5875</issn><issn>1948-5875</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFUUtKBDEUDKL4v4L00k1rOunOZyP4d1BwQGcd0slrJ9KTaNIzoCuv4Fm8h4fwJLbOILpy9QpeVb1HFUI7Bd4rMCn2tUkTsGYMkxa6bg8bjKngS2i9kKXIK8Gr5V94DW2kdI8xk5zjVbRGKSlKQdk6Gp24ZMIM4lMWmmwYOvBdpr3NbqAF07kZZPzj5fXwWTtvQwvZIIVv5HzwkB_pBDYbDujl-1s28GNXuy7EtIVWGt0m2F7MTTQ6O709vsivrs8Hx4dXuS5p2eXCQlPpglZaC2maEoPB1hZMa0y05NJU3BIMteBSMmas4TXhvJSm5sI0pKab6GDu-zCtv-Lon4-6VQ_RTXR8UkE79Xfj3VjdhZnijHHBSW-wuzCI4XEKqVOTPg9oW-0hTJMiJaNYClGxnsrmVBNDShGanzMFVl-dqL-dqEUnvZDMhf1e3Ydp9H0k_4k-AfXQl_k</recordid><startdate>20201112</startdate><enddate>20201112</enddate><creator>Miles, Dillon H</creator><creator>Yan, Xuelei</creator><creator>Thomas-Tran, Rhiannon</creator><creator>Fournier, Jeremy</creator><creator>Sharif, Ehesan U</creator><creator>Drew, Samuel L</creator><creator>Mata, Guillaume</creator><creator>Lawson, Kenneth V</creator><creator>Ginn, Elaine</creator><creator>Wong, Kent</creator><creator>Soni, Divyank</creator><creator>Dhanota, Puja</creator><creator>Shaqfeh, Stefan G</creator><creator>Meleza, Cesar</creator><creator>Chen, Ada</creator><creator>Pham, Amber T</creator><creator>Park, Timothy</creator><creator>Swinarski, Debbie</creator><creator>Banuelos, Jesus</creator><creator>Schindler, Ulrike</creator><creator>Walters, Matthew J</creator><creator>Walker, Nigel P</creator><creator>Zhao, Xiaoning</creator><creator>Young, Stephen W</creator><creator>Chen, Jie</creator><creator>Jin, Lixia</creator><creator>Leleti, Manmohan Reddy</creator><creator>Powers, Jay P</creator><creator>Jeffrey, Jenna L</creator><general>American Chemical Society</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3093-6665</orcidid><orcidid>https://orcid.org/0000-0001-9249-5984</orcidid><orcidid>https://orcid.org/0000-0002-2605-6745</orcidid><orcidid>https://orcid.org/0000-0001-8064-8699</orcidid><orcidid>https://orcid.org/0000-0001-5094-6337</orcidid></search><sort><creationdate>20201112</creationdate><title>Discovery of Potent and Selective 7‑Azaindole Isoindolinone-Based PI3Kγ Inhibitors</title><author>Miles, Dillon H ; Yan, Xuelei ; Thomas-Tran, Rhiannon ; Fournier, Jeremy ; Sharif, Ehesan U ; Drew, Samuel L ; Mata, Guillaume ; Lawson, Kenneth V ; Ginn, Elaine ; Wong, Kent ; Soni, Divyank ; Dhanota, Puja ; Shaqfeh, Stefan G ; Meleza, Cesar ; Chen, Ada ; Pham, Amber T ; Park, Timothy ; Swinarski, Debbie ; Banuelos, Jesus ; Schindler, Ulrike ; Walters, Matthew J ; Walker, Nigel P ; Zhao, Xiaoning ; Young, Stephen W ; Chen, Jie ; Jin, Lixia ; Leleti, Manmohan Reddy ; Powers, Jay P ; Jeffrey, Jenna L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a434t-8def5a135aa89cf40ec0dd16aa02a979c57d20eb879966cdc7b27749cb78cf2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Letter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miles, Dillon H</creatorcontrib><creatorcontrib>Yan, Xuelei</creatorcontrib><creatorcontrib>Thomas-Tran, Rhiannon</creatorcontrib><creatorcontrib>Fournier, Jeremy</creatorcontrib><creatorcontrib>Sharif, Ehesan U</creatorcontrib><creatorcontrib>Drew, Samuel L</creatorcontrib><creatorcontrib>Mata, Guillaume</creatorcontrib><creatorcontrib>Lawson, Kenneth V</creatorcontrib><creatorcontrib>Ginn, Elaine</creatorcontrib><creatorcontrib>Wong, Kent</creatorcontrib><creatorcontrib>Soni, Divyank</creatorcontrib><creatorcontrib>Dhanota, Puja</creatorcontrib><creatorcontrib>Shaqfeh, Stefan G</creatorcontrib><creatorcontrib>Meleza, Cesar</creatorcontrib><creatorcontrib>Chen, Ada</creatorcontrib><creatorcontrib>Pham, Amber T</creatorcontrib><creatorcontrib>Park, Timothy</creatorcontrib><creatorcontrib>Swinarski, Debbie</creatorcontrib><creatorcontrib>Banuelos, Jesus</creatorcontrib><creatorcontrib>Schindler, Ulrike</creatorcontrib><creatorcontrib>Walters, Matthew J</creatorcontrib><creatorcontrib>Walker, Nigel P</creatorcontrib><creatorcontrib>Zhao, Xiaoning</creatorcontrib><creatorcontrib>Young, Stephen W</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Jin, Lixia</creatorcontrib><creatorcontrib>Leleti, Manmohan Reddy</creatorcontrib><creatorcontrib>Powers, Jay P</creatorcontrib><creatorcontrib>Jeffrey, Jenna L</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miles, Dillon H</au><au>Yan, Xuelei</au><au>Thomas-Tran, Rhiannon</au><au>Fournier, Jeremy</au><au>Sharif, Ehesan U</au><au>Drew, Samuel L</au><au>Mata, Guillaume</au><au>Lawson, Kenneth V</au><au>Ginn, Elaine</au><au>Wong, Kent</au><au>Soni, Divyank</au><au>Dhanota, Puja</au><au>Shaqfeh, Stefan G</au><au>Meleza, Cesar</au><au>Chen, Ada</au><au>Pham, Amber T</au><au>Park, Timothy</au><au>Swinarski, Debbie</au><au>Banuelos, Jesus</au><au>Schindler, Ulrike</au><au>Walters, Matthew J</au><au>Walker, Nigel P</au><au>Zhao, Xiaoning</au><au>Young, Stephen W</au><au>Chen, Jie</au><au>Jin, Lixia</au><au>Leleti, Manmohan Reddy</au><au>Powers, Jay P</au><au>Jeffrey, Jenna L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of Potent and Selective 7‑Azaindole Isoindolinone-Based PI3Kγ Inhibitors</atitle><jtitle>ACS medicinal chemistry letters</jtitle><addtitle>ACS Med. Chem. Lett</addtitle><date>2020-11-12</date><risdate>2020</risdate><volume>11</volume><issue>11</issue><spage>2244</spage><epage>2252</epage><pages>2244-2252</pages><issn>1948-5875</issn><eissn>1948-5875</eissn><abstract>The successful application of immunotherapy in the treatment of cancer relies on effective engagement of immune cells in the tumor microenvironment. Phosphoinositide 3-kinase γ (PI3Kγ) is highly expressed in tumor-associated macrophages, and its expression levels are associated with tumor immunosuppression and growth. Selective inhibition of PI3Kγ offers a promising strategy in immuno-oncology, which has led to the development of numerous potent PI3Kγ inhibitors with variable selectivity profiles. To facilitate further investigation of the therapeutic potential of PI3Kγ inhibition, we required a potent and PI3Kγ-selective tool compound with sufficient metabolic stability for use in future in vivo studies. Herein, we describe some of our efforts to realize this goal through the systematic study of SARs within a series of 7-azaindole-based PI3Kγ inhibitors. The large volume of data generated from this study helped guide our subsequent lead optimization efforts and will inform further development of PI3Kγ-selective inhibitors for use in immunomodulation.</abstract><pub>American Chemical Society</pub><pmid>33214836</pmid><doi>10.1021/acsmedchemlett.0c00387</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3093-6665</orcidid><orcidid>https://orcid.org/0000-0001-9249-5984</orcidid><orcidid>https://orcid.org/0000-0002-2605-6745</orcidid><orcidid>https://orcid.org/0000-0001-8064-8699</orcidid><orcidid>https://orcid.org/0000-0001-5094-6337</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1948-5875 |
| ispartof | ACS medicinal chemistry letters, 2020-11, Vol.11 (11), p.2244-2252 |
| issn | 1948-5875 1948-5875 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7667872 |
| source | ACS Publications; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Letter |
| title | Discovery of Potent and Selective 7‑Azaindole Isoindolinone-Based PI3Kγ Inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T09%3A58%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20Potent%20and%20Selective%207%E2%80%91Azaindole%20Isoindolinone-Based%20PI3K%CE%B3%20Inhibitors&rft.jtitle=ACS%20medicinal%20chemistry%20letters&rft.au=Miles,%20Dillon%20H&rft.date=2020-11-12&rft.volume=11&rft.issue=11&rft.spage=2244&rft.epage=2252&rft.pages=2244-2252&rft.issn=1948-5875&rft.eissn=1948-5875&rft_id=info:doi/10.1021/acsmedchemlett.0c00387&rft_dat=%3Cproquest_pubme%3E2463098856%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2463098856&rft_id=info:pmid/33214836&rfr_iscdi=true |